Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Harvard Bioscience (HBIO) Return on Sales (2016 - 2025)

Harvard Bioscience (HBIO) has disclosed Return on Sales for 16 consecutive years, with 0.06% as the latest value for Q3 2025.

  • On a quarterly basis, Return on Sales rose 16.0% to 0.06% in Q3 2025 year-over-year; TTM through Sep 2025 was 0.77%, a 62.0% decrease, with the full-year FY2024 number at 0.13%, down 10.0% from a year prior.
  • Return on Sales was 0.06% for Q3 2025 at Harvard Bioscience, up from 0.11% in the prior quarter.
  • In the past five years, Return on Sales ranged from a high of 0.08% in Q2 2022 to a low of 2.31% in Q1 2025.
  • A 5-year average of 0.21% and a median of 0.06% in 2023 define the central range for Return on Sales.
  • Peak YoY movement for Return on Sales: grew 27bps in 2023, then plummeted -212bps in 2025.
  • Harvard Bioscience's Return on Sales stood at 0.02% in 2021, then plummeted by -421bps to 0.06% in 2022, then dropped by -1bps to 0.06% in 2023, then plummeted by -825bps to 0.54% in 2024, then skyrocketed by 89bps to 0.06% in 2025.
  • Per Business Quant, the three most recent readings for HBIO's Return on Sales are 0.06% (Q3 2025), 0.11% (Q2 2025), and 2.31% (Q1 2025).